US4913907A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Porphycene anti-cancer agents and treatment methods
Assignee: Cytopharm Inc
•
Filing: 1988-08-15
•
Granted: 1990-04-03
•
Expires: 2008-08-15
Abstract
Abstract The therapeutic compositions of this invention comprise one or more porphycene compounds incorporated within liposomes. The method of this invention for treating cancer comprises administering a therapeutically effective amount of a porphycene derivative to a patient, and exposing an affected body area of the patient to a therapeutically sufficient amount of light having a wavelength of from 600 to 950 nm.
Inventors
- 👤 Giulio Jori
- 👤 Matthias Kocher
- 👤 Emanuel Vogel
- 👤 Alexander D. Cross
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:11
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K9/00; A61K9/10; A61K9/127
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
65 words
A liposome including at least one porphycene of Formula I or Formula II: ##STR5## wherein R 1 , R 2 , R 3 , and R 4 are hydrogen or a lower alkyl having from 1 to 6 carbons; ##STR6## wherein R 5 , R 6 , R 7 , and R 8 are hydrogen or a lower alkyl having from 1 to 6 carbons.
Claim 2
Dependent Claim
65 words
A liposome including at least one porphycene of Formula I or Formula II: ##STR5## wherein R 1 , R 2 , R 3 , and R 4 are hydrogen or a lower alkyl having from 1 to 6 carbons; ##STR6## wherein R 5 , R 6 , R 7 , and R 8 are hydrogen or a lower alkyl having from 1 to 6 carbons.
Claim 3
Dependent Claim
8 words
A liposome according to claim 1 including Porphycene.
Claim 4
Dependent Claim
13 words
A liposome according to claim 1 including a porphycene compound of Formula I.
Claim 5
Dependent Claim
25 words
A liposome according to claim 3 including a porphycene compound selected from the group consisting of 2,7,12,17-tetramethylporphycene, 2,7,12,17-tetraethylporphycene, 2,7,12,17-tetra-n-propylporphycene, 2,7,12,17-tetra-n-butylporphycene, 2,7,12,17-tetra-n-pentylporphycene, 2,7,12,17-tetra-n-hexylporphycene, and mixtures thereof.
Claim 6
Dependent Claim
13 words
A liposome according to claim 1 including a porphycene compound of Formula II.
Claim 7
Dependent Claim
25 words
A liposome according to claim 5 including a porphycene compound selected from the group consisting of 9,10,19,20-tetramethylporphycene, 9,10,19,20-tetraethylporphycene, 9,10,19,20-tetra-n-propylporphycene, 9,10,19,20-tetra-n-butylporphycene, 9,10,19,20-tetra-n-pentylprophycene, 9,10,19,20-tetra-n-hexylporphycene, and mixtures thereof.
Claim 8
Dependent Claim
11 words
A liposome according to claim 1 wherein the liposome is unilamellar.
Claim 9
Dependent Claim
11 words
A liposome according to claim 1 wherein the liposome is multilamellar.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-02 | 1993-10-02 | 1994-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-02 | 1997-10-02 | 1998-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-02 | 2001-10-02 | 2002-04-03 | $7700.00 | Window Closed / Lapsed |